AUTHOR=Bhattarai Umesh , He Xiaochen , Niu Ziru , Pan Lihong , Wang Dongzhi , Wang Hao , Zeng Heng , Chen Jian-Xiong , Speed Joshua S. , Clemmer John S. , Chen Yingjie 

TITLE=Pharmacological inhibition of IL12β is effective in treating pressure overload-induced cardiac inflammation and heart failure

JOURNAL=Frontiers in Immunology

VOLUME=Volume 16 - 2025

YEAR=2025

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1624940

DOI=10.3389/fimmu.2025.1624940

ISSN=1664-3224

ABSTRACT=Background and objectiveEmerging evidence indicates that inflammation regulates cardiac remodeling and heart failure (HF). IL12β is a subunit for proinflammatory cytokines IL12 and IL23. However, the effect of IL12β inhibition on HF development and the underlying mechanism is not understood.MethodsWe determined the effect of pharmacological inhibition of IL12β using IL12β blocking antibody on transverse aortic constriction (TAC)-induced left ventricular (LV) inflammation and HF development.ResultsIL12β blocking antibody significantly attenuated TAC-induced LV immune cell infiltration, hypertrophy, fibrosis, dysfunction, and the consequent pulmonary inflammation and remodeling. More specifically, we found that IL12β blocking antibody significantly attenuated TAC-induced LV and pulmonary infiltration of neutrophils, macrophages, CD11c+ dendritic cells, CD8+ T cells, and CD4+ T cells. Moreover, IL12β blocking antibody significantly suppressed the production of pro-inflammatory cytokine pro-IL1β and IFNγ by macrophages and IFNγ by CD8+ T cells and/or CD4+ T cells.ConclusionsThese findings indicate that pharmacological inhibition of IL12β effectively protected the heart from systolic overload-induced inflammation, remodeling, and dysfunction by reducing the proinflammatory signaling from both innate and adaptive immune responses.